UKROC review of treatments and outcomes in metastatic renal cancer
Research type
Research Study
Full title
UK Renal Oncology Collaborative - Real world review of therapy choices and outcomes in metastatic renal cancer
IRAS ID
338935
Contact name
John McGrane
Contact email
Sponsor organisation
Royal Cornwall Hospital
Clinicaltrials.gov Identifier
2324.RCHT.69, RCHT R&D ref
Duration of Study in the UK
1 years, 4 months, 1 days
Research summary
The treatment landscape of metastatic renal cell carcinoma (mRCC) has evolved over the last few years with several systemic anti-cancer therapies (SACT) licensed across different lines of treatment.
A previous real world study in the UK had demonstrated a significant attrition rate between each line of therapy suggesting less than half of patients who received first line SACT then received second line therapy and less than a fifth of first line SACT patients reach third line. We are reviewing the survival outcomes for patients based on initial therapy type, risk group and cancer subtype and spread.REC name
South Central - Hampshire B Research Ethics Committee
REC reference
24/SC/0038
Date of REC Opinion
9 Feb 2024
REC opinion
Further Information Favourable Opinion